CP

Mosaic Immunoengineering IncOOTC CPMV Stock Report

Last reporting period 30 Sep, 2023

Updated 19 Nov, 2024

Last price

Market cap $B

0.007

Micro

Exchange

OOTC - OTC

CPMV Stock Analysis

CP

Uncovered

Mosaic Immunoengineering Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.007

Dividend yield

Shares outstanding

7.242 B

Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company, which engages in the development of biotechnology products. The company is headquartered in Huntington Beach, California and currently employs 4 full-time employees. The firm is focused on developing and commercializing its immunomodulator platform technology designed to activate the innate immune system to treat and prevent cancer and infectious diseases. The Company’s lead immunomodulator product candidate, MIE-101, which is based on a naturally occurring plant virus known as Cowpea mosaic virus (CPMV) which is held to be non-infectious in animals including mice, dogs, and humans. The product is injected directly into a tumor and can act as an in-situ vaccine using markers of the injected tumor as the target which results in the activation of a robust immune response against the primary tumor and to prime systemic anti-tumor immunity, while reversing immunosuppressive signals in the tumor microenvironment (TME). The Company’s immunomodulator platform technology has also been used to produce modular vaccines under its modular vaccine platform (MVP).

View Section: Eyestock Rating